Repare Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$2.11(as of Nov 17, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Repare Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$2.11
Ticker SymbolRPTX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees129
CountyUSA
Market Cap$72.6M
EBIDTA-110.5M
10-Day Moving Average1.76
P/E Ratio-1.30
20-Day Moving Average1.81
Forward P/E Ratio0.00
50-Day Moving Average1.79
Earnings per Share-2.58
200-Day Moving Average1.46
Profit MarginInfinity%
RSI72.40
Shares Outstanding43.0M
ATR0.11
52-Week High4.07
Volume7,490,635
52-Week Low0.89
Most Recent Support Level1.65
Book Value115.1M
Most Recent Resistance Level1.87
P/B Ratio0.82
Upper Keltner2.06
P/S Ratio-1.76
Lower Keltner1.56
Debt-to-Equity Ratio2.06
Next Earnings DateUnknown
Cash Surplus61.2M
Next Ex-Dividend DateUnknown

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.

Repare Therapeutics Inc In Our Stock Scanner

As of Nov 18, 2025
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low PS RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.